UnknownPhase 2

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

China22 participantsStarted 2018-10-10

Plain-language summary

The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Must be ≥ 18 years;
✓. Understand and voluntarily sign an ICD prior to any study related assessments/procedures are conducted;
✓. Diagnosis of acquired hemophilia A；
✓. acute bleeding episodes(≥once).

Exclusion criteria

✕. Uncontrolled systemic infection;
✕. Allergy to rituximab;
✕. Positive for Lupus anticoagulant;
✕. Life expectancy \< 3 months;
✕. Pregnant and breastfeeding women;
✕. Neuropathy\>Grade 1;
✕. Positive for Hepatitis B surface antigen or hepatitis C antibody or human immunodeficiency virus（HIV）antibody;
✕. Patients with poor compliance；

What they're measuring

The time to attain first complete remission (CR)

Timeframe: Last day of the treatment regimen (up to 3 months)

Trial details

NCT IDNCT03700229

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10-15

Contact for this trial

Huacong Cai

01069158271 caihc@pumch.cn

View on ClinicalTrials.gov More Acquired Hemophilia A trials